Ranolazine: an anti-anginal drug with further therapeutic potential

References

• Lloyd-Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics – 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation119, 480–486 (2009).
   PubMed Web of Science ®Google Scholar
• Fox K, Garcia MA, Ardissino D et al. Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European Society of Cardiology. Eur. Heart J.27, 1341–1381 (2006).
   PubMed Web of Science ®Google Scholar
• Legrand VM, Serruys PW, Unger F et al. Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation109, 1114–1120 (2004).
   PubMed Web of Science ®Google Scholar
• Boden WE, O’Rourke RA, Teo KK et al. Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med.356, 1503–1516 (2007).
   PubMed Web of Science ®Google Scholar
• Weintraub WS, Spertus JA, Kolm P et al. Effect of PCI on quality of life in patients with stable coronary disease. N. Engl. J. Med.359, 677–687 (2008).
   PubMed Web of Science ®Google Scholar
• Michaelsen A, Knoblauch NT, Lehmann N et al. Effects of lifestyle modification on the progression of coronary atherosclerosis, autonomic function, and angina – the role of GNB3 C825T polymorphism. Am. Heart J.151, 870–877 (2006).
   Google Scholar
• Ahern GP, Hsu SF, Klyachko VA, Jackson MB. Induction of persistent sodium current by exogenous and endogenous nitric oxide. J. Biol. Chem.275, 28810–28815 (2000).
   PubMed Web of Science ®Google Scholar
• Undrovinas AI, Fleidervish IA, Makielski JC. Inward sodium current at resting potential in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine. Circ. Res.71, 1231–1241 (1992).
   PubMed Web of Science ®Google Scholar
• Wu J, Corr PB. Palmitoyl carnithine modifies sodium currents and induces transient inward current in ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol.266, H1034–H1046 (1994).
   Google Scholar
• Hale SL, Shryock JC, Belardinelli L, Sweeney M, Kloner RA. Late sodium current inhibition as a new cardioprotective approach. J. Mol. Cell. Cardiol.44, 954–967 (2008).
   PubMed Web of Science ®Google Scholar
• Gaffney SM. Ranolazine, a novel agent for chronic stable angina. Pharmacotherapy26, 135–142 (2006).
   PubMed Web of Science ®Google Scholar
• Song Y, Shryock JC, Wagner S et al. Blocking late sodium current reduces hydrogen-peroxide-induced arrhythmogenic activity and contractile dysfunction. J. Pharmacol. Exp. Ther.318, 214–222 (2006).
   PubMed Web of Science ®Google Scholar
• Song Y, Shryock JC, Wu L et al. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J. Cardiovasc. Pharmacol.44, 192–199 (2004).
   PubMed Web of Science ®Google Scholar
• Fraser H, Belardinelli L, Wang L, Light PE, McVeigh JJ, Clanachan AS. Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J. Mol. Cell. Cardiol.41, 1031–1038 (2006).
   PubMed Web of Science ®Google Scholar
• Fredj S, Sampson KJ, Liu H et al. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br. J. Pharmacol.148, 16–24 (2006).
   PubMed Web of Science ®Google Scholar
• Moos AJ, Zareba W, Schwarz KQ et al. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J. Cardiovasc. Electrophysiol.19, 1289–1293 (2008).
   Google Scholar
• Antzelevitch C, Belardinelli L, Zygmunt AC et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation110, 904–910 (2004).
   PubMed Web of Science ®Google Scholar
• Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart92(Suppl. 4), IV6–IV14 (2006).
   PubMed Web of Science ®Google Scholar
• Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J. Cardiovasc. Electrophysiol.17(Suppl. 1), S169–S177 (2006).
   PubMedGoogle Scholar
• Wu L, Shryock JC, Song Y, Antzelevitch C, Belardinelli L. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long QT-syndrome. J. Pharmacol. Exp. Ther.310, 599–605 (2004).
   PubMed Web of Science ®Google Scholar
• Wu L, Shryock JC, Song Y, Belardinelli L. An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts. J. Pharmcol. Exp. Ther.316, 718–726 (2006).
   Google Scholar
• Gralinski MR, Chi L, Park JL et al. Protective effects of ranolazine on ventricular fibrillation induced by activation of the ATP-dependent potassium channel in the rabbit heart. J. Cardiovasc. Pharmacol. Ther.1, 141–148 (1996).
   Google Scholar
• Scirica BM, Morrow DA, Hod H et al. Effects of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation116, 1647–1652 (2007).
   PubMed Web of Science ®Google Scholar
• Wang P, Fraser H, Lloyd SG, McVeigh JJ, Belardinelli L, Chatham JC. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion. J. Pharmacol. Exp. Ther.321, 213–220 (2007).
   PubMed Web of Science ®Google Scholar
• Clarke B, Wyatt KM, McCormack JG. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. J. Mol. Cell. Cardiol.28, 341–350 (1996).
   PubMed Web of Science ®Google Scholar
• McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation93, 135–142 (1996).
   PubMed Web of Science ®Google Scholar
• MacInnes A, Fairman DA, Binding P et al. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res.93, e33–e37 (2003).
   Google Scholar
• Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur. Heart J.27, 42–48 (2006).
   PubMed Web of Science ®Google Scholar
• Morrow DA, Scirica MB, Chaitman BR et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation119, 2032–2039 (2009).
   PubMed Web of Science ®Google Scholar
• Létienne R, Vie B, Puech A, Vieu S, Le Grand B, John GW. Evidence that ranolazine behaves as a weak β1 and β2-adrenoceptor antagonist in the rat cardiovascular system. Naunyn-Schmiedeberg’s Arch. Pharmacol.363, 464–471 (2001).
   Google Scholar
• Chaitman BR, Skettino SL, Parker JO et al. Anti-ischemic effects and long term survival during ranolazine monotherapy in patients with chronic severe angina. J. Am. Coll. Cardiol.43, 1375–1382 (2004).
   PubMed Web of Science ®Google Scholar
• Cocco G, Rousseasu MF, Bouvy T et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with b-blocker or diltiazem. J. Cardiovasc. Pharmacol.20, 131–138 (1992).
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Wolff AA; Ranolazine Study Group. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Am. J. Cardiol.84, 46–50 (1999).
   PubMed Web of Science ®Google Scholar
• Thadani U, Ezekowitz M, Fenney L et al. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Circulation90, 726–734 (1994).
   PubMed Web of Science ®Google Scholar
• Chaitman BR, Pepine CJ, Parker JO et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. A randomized controlled trial. JAMA291, 309–316 (2004).
   PubMed Web of Science ®Google Scholar
• Stone PH, Gratsiansky NA, Blokhin A et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J. Am. Coll. Cardiol.48, 566–575 (2006).
   PubMed Web of Science ®Google Scholar
• Clarke B, Spedding M, Patmore L, McCormack JG. Protective effects of ranolazine in guinea pig hearts during low-flow ischaemia and their association with increases in pyruvate dehydrogenase. Br. J. Pharmacol.109, 748–750 (1993).
   PubMed Web of Science ®Google Scholar
• Zacharowski K, Blackburn B, Thiemermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduced myocardial infarct size and cardiac troponin release in the rat. Eur. J. Pharmacol.418, 105–110 (2001).
   PubMedGoogle Scholar
• Hale SL, Leeka JA, Kloner RA. Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channel. J. Pharmacol. Exp. Ther.318, 418–423 (2006).
   PubMed Web of Science ®Google Scholar
• Hale SL, Kloner RA. The antianginal agent, ranolazine, reduces myocardial infarct size but does not alter anatomic no-reflow or regional myocardial blood flow in ischemia/reperfusion in the rabbit. J. Cardiovasc. Pharmacol. Ther.13, 226–232 (2008).
   PubMed Web of Science ®Google Scholar
• Black SC, Gralinski MR, McCormack JG, Driscoll EM, Lucchesi BR. Effects of ranolazine on infarct size in a canine model of regional myocardial ischemia/reperfusion. J. Cardiovasc. Pharmacol.24, 921–928 (1994).
   PubMed Web of Science ®Google Scholar
• Hale SL, Kloner RA. Ranolazine, an inhibitor of the late sodium channel current, reduces postischemic myocardial dysfunction in the rabbit. J. Cardiovasc. Pharmacol. Ther.11, 249–255 (2006).
   PubMed Web of Science ®Google Scholar
• Sabbah HN, Chandler MP, Mishima T et al. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J. Card. Fail.8, 416–422 (2002).
   PubMed Web of Science ®Google Scholar
• Aaker A, McCormack JG, Hirai T, Musch TI. Effects of ranolazine on the exercise capacity of rats with chronic heart failure induced by myocardial infarction. J. Cardiovasc. Pharmacol.28, 353–362 (1999).
   Google Scholar
• Keating GM. Ranolazine. A review of its use in chronic stable angina pectoris. Drugs68, 2483–2503 (2008).
   PubMed Web of Science ®Google Scholar
• Jerling M. Clinical pharmacokinetics of ranolazine. Clin. Pharmacokinet.45, 469–491 (2006).
   PubMed Web of Science ®Google Scholar
• Penman AD, Eadie J, Herron WJ et al. The characterization of the metabolism of ranolazine in man by liquid chromatography mass spectroscopy. Rapid Comun. Mass Spectrom.9, 1418–1430 (1995).
   PubMed Web of Science ®Google Scholar
• Abdallah H, Jerling M. Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets. J. Clin. Pharmacol.45, 802–809 (2005).
   PubMed Web of Science ®Google Scholar
• Jerling M, Abdallah H. Effect of renal impairment on multiple-dose pharmocokinetics of extended-release ranolazine. Clin. Pharmacol. Ther.78, 288–297 (2005).
   PubMed Web of Science ®Google Scholar
• Jain D, Dasgupta P, Hughes LO, Lahiri A, Raftery EB. Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium. Eur. J. Clin. Pharmacol.38, 111–114 (1990).
   PubMedGoogle Scholar
• Rousseau MF, Pouleur H, Cocco G, Wolf AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am. J. Cardiol.95, 311–316 (2005).
   PubMed Web of Science ®Google Scholar
• Venkataraman R, Belardinelli L, Blackburn B, Heo J, Iskandrian AE. A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images. JACC Cardiovasc. Imaging2, 1301–1309 (2009).
   PubMedGoogle Scholar
• Morrow DA, Scirica BM, Karwatowska-Prokopczuk E et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA297, 1775–1783 (2007).
   PubMed Web of Science ®Google Scholar
• Wilson SR, Scirica BM, Braunwald E et al. Efficacy of ranolazine in patients with chronic angina. J. Am. Coll. Cardiol.53, 1510–1516 (2009).
   PubMed Web of Science ®Google Scholar
• Wenger NK, Chaitman B, Vetrovec GW. Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials. Am. J. Cardiol.99, 11–18 (2007).
   PubMedGoogle Scholar
• Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). J. Am. Coll. Cardiol.49, 1027–1034 (2007).
   PubMed Web of Science ®Google Scholar
• Hasenfuss G, Schillinger W, Lehnart SE et al. Relationship between Na+–Ca2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation99, 641–648 (1999).
   PubMed Web of Science ®Google Scholar
• Sossalla S, Wagner S, Rasenack ECL et al. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts – role of late sodium current and intracellular ion accumulation. J. Mol. Cell. Cardiol.45, 32–43 (2008).
   PubMed Web of Science ®Google Scholar
• Hayashida W, van Eyll C, Rousseau MF, Pouleur H. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc. Drugs Ther.8, 741–747 (1994).
   PubMed Web of Science ®Google Scholar
• Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, Robinson JL. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long QT syndrome. J. Cardiovasc. Electrophysiol.19, 1289–1293 (2008).
   PubMed Web of Science ®Google Scholar
• Hwang H, Arcidi JM, Hale SL et al. Ranolazine as a cardioplegia additive improves recovery of diastolic function in isolated rat hearts. Circulation120, S16–S21 (2009).
   Google Scholar
• Hwang H, Arcidi JM, Hale SL et al. Ranolazine as an adjunct to cardioplegia: a potential new therapeutic application. J. Cardiovasc. Pharmacol. Ther.14, 125–133 (2009).
   Google Scholar
• Antzelevich C, Burashnikov A. Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation. J. Electrocardiogr.42(6), 543–548 (2009).
   Google Scholar
• Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation116, 1449–1457 (2007).
   PubMed Web of Science ®Google Scholar
• Burashnikov A, Antzelevitch C. Atrial-selective sodium channel blockers: do they exist? J. Cardiovasc. Pharmacol.52, 121–128 (2008).
   PubMed Web of Science ®Google Scholar
• Kumar K, Nearing BD, Carvas M et al. Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. J. Cardiovasc. Electrophysiol.20, 796–802 (2009).
   PubMed Web of Science ®Google Scholar
• Dhalla AK, Wang WQ, Dow J et al. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am. J. Physiol. Am. Heart Circ. Physiol.297(5), H1923–H1929 (2009).
   Google Scholar
• Kumar K, Nearing BD, Bartolli CR et al. Effect of ranolazine on ventricular vulnerability and defibrillation threshold in the intact porcine heart. J. Cardiovasc. Electrophysiol.19, 1073–1079 (2008).
   Google Scholar